c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells
- PMID: 20221419
- PMCID: PMC2835311
- DOI: 10.1007/s12265-009-9150-5
c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells
Abstract
Induced pluripotent stem cell (iPS) technology has launched a new platform in regenerative medicine aimed at deriving unlimited replacement tissue from autologous sources through somatic cell reprogramming using stemness factor sets. In this way, authentic cardiomyocytes have been obtained from iPS and recently demonstrated in proof-of-principle studies to repair infarcted heart. Optimizing the cardiogenic potential of iPS progeny would ensure a maximized yield of bioengineered cardiac tissue. Here, we reprogrammed fibroblasts in the presence or absence of c-MYC to determine if the acquired cardiogenicity is sensitive to the method of nuclear reprogramming. Using lentiviral constructs that expressed stemness factors SOX2, OCT4, and KLF4 with or without c-MYC, iPS clones generated through fibroblast reprogramming demonstrated indistinguishable characteristics for 5 days of differentiation with similar cell morphology, growth rates, and chimeric embryo integration. However, 4-factor c-MYC dependent nuclear reprogramming produced iPS progeny that consistently prolonged the expression of pluripotent Oct-4 and Fgf4 genes and repressed cardiac differentiation. In contrast, 3-factor c-MYC-less iPS clones efficiently up-regulated pre-cardiac (CXCR4, Flk-1, and Mesp1/2) and cardiac (Nkx2.5, Mef2c, and Myocardin) gene expression patterns. In fact, 3-factor iPS progeny demonstrated early and robust cardiogenesis during in vitro differentiation with consistent beating activity, sarcomere maturation, and rhythmical intracellular calcium dynamics. Thus, nuclear reprogramming independent of c-MYC enhances production of pluripotent stem cells with innate cardiogenic potential.
Figures






Similar articles
-
iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism.Circ Res. 2009 Sep 25;105(7):648-56. doi: 10.1161/CIRCRESAHA.109.203109. Epub 2009 Aug 20. Circ Res. 2009. PMID: 19696409 Free PMC article.
-
Natural cardiogenesis-based template predicts cardiogenic potential of induced pluripotent stem cell lines.Circ Cardiovasc Genet. 2013 Oct;6(5):462-71. doi: 10.1161/CIRCGENETICS.113.000045. Epub 2013 Sep 14. Circ Cardiovasc Genet. 2013. PMID: 24036272 Free PMC article.
-
Generation of pig iPS cells: a model for cell therapy.J Cardiovasc Transl Res. 2011 Apr;4(2):121-30. doi: 10.1007/s12265-010-9233-3. Epub 2010 Nov 19. J Cardiovasc Transl Res. 2011. PMID: 21088946
-
[Induction and characterization of induced pluripotent stem (iPS) cells: a review].Sheng Wu Gong Cheng Xue Bao. 2010 Apr;26(4):421-30. Sheng Wu Gong Cheng Xue Bao. 2010. PMID: 20575428 Review. Chinese.
-
Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs).J Stem Cells. 2015;10(1):43-62. J Stem Cells. 2015. PMID: 26665937 Review.
Cited by
-
iPS cell-derived cardiogenicity is hindered by sustained integration of reprogramming transgenes.Circ Cardiovasc Genet. 2014 Oct;7(5):667-76. doi: 10.1161/CIRCGENETICS.113.000298. Epub 2014 Jul 30. Circ Cardiovasc Genet. 2014. PMID: 25077947 Free PMC article.
-
Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny.Gene Ther. 2011 Mar;18(3):283-93. doi: 10.1038/gt.2010.145. Epub 2010 Nov 4. Gene Ther. 2011. PMID: 21048796 Free PMC article.
-
Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming.Cell Stem Cell. 2012 Jan 6;10(1):16-28. doi: 10.1016/j.stem.2011.12.013. Cell Stem Cell. 2012. PMID: 22226352 Free PMC article.
-
Induced pluripotent stem cells: developmental biology to regenerative medicine.Nat Rev Cardiol. 2010 Dec;7(12):700-10. doi: 10.1038/nrcardio.2010.159. Epub 2010 Oct 19. Nat Rev Cardiol. 2010. PMID: 20956984 Review.
-
Human cardiomyogenesis and the need for systems biology analysis.Wiley Interdiscip Rev Syst Biol Med. 2011 Nov-Dec;3(6):666-80. doi: 10.1002/wsbm.141. Epub 2010 Dec 31. Wiley Interdiscip Rev Syst Biol Med. 2011. PMID: 21197666 Free PMC article. Review.
References
-
- Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell. 2007;1(1):39–49. - PubMed
-
- Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676. - PubMed
-
- Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448(7151):313–317. - PubMed
-
- Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007;448(7151):318–324. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources